Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 15/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 15/20 | 0.43 |
| ▸ | ITGAV | P06756 | 2/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13026931 | 0.82 | GPR119 (0.43) | HRH2HRH1GPR119KCNH2 | |
| SCHEMBL8066595 | 0.82 | ITGB3 (0.50) | ITGB3ITGA2BITGAVGPR119CHRM2 | |
| SCHEMBL865123 | 0.81 | KCNH2 (0.47) | KCNH2F2PRSS1 | |
| SCHEMBL865122 | 0.81 | KCNH2 (0.47) | KCNH2F2PRSS1 | |
| SCHEMBL864087 | 0.78 | CYP3A4 (0.44) | KCNH2 | |
| SCHEMBL864086 | 0.78 | CYP3A4 (0.44) | KCNH2 | |
| SCHEMBL8066147 | 0.77 | ELANE (0.35) | HRH2HRH1F2PRSS1 | |
| SCHEMBL8058055 | 0.77 | ELANE (0.36) | HRH2HRH1GPR119F2PRSS1 | |
| SCHEMBL2897630 | 0.74 | HRH2 (0.36) | HRH2HRH1GPR119KCNH2 | |
| SCHEMBL2897008 | 0.74 | HRH2 (0.36) | HRH2HRH1KCNH2F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009034388-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |